Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

20.86 -1.95 (-8.55%)
Streaming Delayed Price Updated: 2:11 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,252,609
Open 21.49
Bid (Size) 20.85 (1)
Ask (Size) 20.87 (1)
Prev. Close 22.81
Today's Range 19.50 - 21.70
52wk Range 1.640 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga

Performance

YTD
+690.15%
+690.15%
1 Month
+54.86%
+54.86%
3 Month
+165.06%
+165.06%
6 Month
+403.86%
+403.86%
1 Year
+986.46%
+986.46%

More News

Read More
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
Via The Motley Fool
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via AB Newswire
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
Via The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Via Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
Via The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
From Summit Therapeutics Inc.
Via Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Via Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Via The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
Via The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
Via The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
Via Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
Via MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
Via Benzinga
Summit Therapeutics Raises $235 Million
From Summit Therapeutics Inc.
Via Business Wire
Is Summit Therapeutics a Buy Now?
Via The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.